Patents Issued in September 26, 2019
  • Publication number: 20190290666
    Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 26, 2019
    Inventor: Michael A. Schmidt
  • Publication number: 20190290667
    Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventors: Elise CHAMPION, Bruce MCCONNELL, Gyula DEKANY
  • Publication number: 20190290668
    Abstract: A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 26, 2019
    Inventors: Norbert Sprenger, Clemens Kunz, Dominique Brassart
  • Publication number: 20190290669
    Abstract: The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. In particular, the present invention relates to N-palmitoyl-D-glucosamine in a micronized or co-micronized form with Curcumin. Such a product can be formulated in human or veterinary pharmaceutical compositions, dietetic products, food supplements, or foods for special medical purposes (FSMP), or in feeds, or nutritional supplements for animals for the treatment of chronic systemic inflammatory diseases, in humans and animals, resulting from dysfunctions of epithelia and synovial membranes.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Applicant: Innovet Italia S.R.L.
    Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Sofia Parrasia, Salvatore Cuzzocrea
  • Publication number: 20190290670
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: June 13, 2019
    Publication date: September 26, 2019
    Inventors: Jean-Pierre Sommadossi, Paolo La Colla
  • Publication number: 20190290671
    Abstract: Disclosed are the hypolipidemic effects of a composition comprising at least 10% w/w or above of 1-O-galloyl-?-D-glucose (?-glucogallin). The composition is effective in reducing the circulating levels of total cholesterol, triglycerides, LDL, cholesterol:HDL ratio and increasing HDL levels. The invention also discloses a method for reducing absorption and bio-accessibility of lipids in mammals using the abovementioned composition.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 26, 2019
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Shaheen Majeed, Anurag Pande
  • Publication number: 20190290672
    Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 26, 2019
    Inventors: Michael WITTEKIND, Raymond SCHUCH
  • Publication number: 20190290673
    Abstract: This invention relates to methods useful in the treatment of a hepatitis infection.
    Type: Application
    Filed: October 24, 2017
    Publication date: September 26, 2019
    Inventors: Radhakrishnan P. Iyer, Rayomand H. Gimi
  • Publication number: 20190290674
    Abstract: According to the present invention, various diseases, such as viral diseases, cancer, and multiple sclerosis, can be prevented and improved by using an immunostimulatory factor production-promoting composition comprising genomic double-stranded RNA of a plant-derived endornavirus.
    Type: Application
    Filed: July 31, 2017
    Publication date: September 26, 2019
    Applicant: Kyoto University
    Inventors: Takashi FUJITA, Hiroki KATO, Tetsuya NAKAZAKI
  • Publication number: 20190290675
    Abstract: Compositions of glycan polymers and methods of making and manufacturing the same are described herein. Also provided are methods of treating a disease or disorder with a glycan polymer preparation.
    Type: Application
    Filed: December 6, 2017
    Publication date: September 26, 2019
    Inventors: Molly Krisann Gibson, Christopher Matthew Liu, Geoffrey A. von Maltzahn, Han Yuan
  • Publication number: 20190290676
    Abstract: An antibacterial wound dressing, a method for preparing the antibacterial wound dressing, and a use of the antibacterial wound dressing are provided. The antibacterial wound dressing is obtained by amidating carboxymethyl cellulose with a guanidine compound. The carboxymethyl cellulose has a substitution degree of 0.1-0.6, and the guanidine compound has a grafting degree of 0.2%-10.0%.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Applicant: Huizhou Foryou Medical Devices Co., Ltd.
    Inventors: Junfeng ZHANG, Jinwen MO, Jie DONG
  • Publication number: 20190290677
    Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
    Type: Application
    Filed: June 4, 2019
    Publication date: September 26, 2019
    Inventors: Bernardus Nicolaas Machielse, Allan Darling
  • Publication number: 20190290678
    Abstract: The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement.
    Type: Application
    Filed: April 12, 2019
    Publication date: September 26, 2019
    Inventors: Je Hyeon Lee, Moon Hee Lee, Sun Joo Hong, Soon Kwang Hong
  • Publication number: 20190290679
    Abstract: A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Applicant: ECONUGENICS INC
    Inventor: ISAAC ELIAZ
  • Publication number: 20190290680
    Abstract: The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.
    Type: Application
    Filed: July 15, 2017
    Publication date: September 26, 2019
    Applicant: President and Fellows of Harvard College
    Inventors: Sungwhan Oh, Deniz Erturk-Hasdemir, Dennis L. Kasper
  • Publication number: 20190290681
    Abstract: Provided herein are compositions, systems, kits, and methods for treating a viral, bacterial, protozoan, and/or fungal (e.g., onychomycosis and/or tinea pedis) infection.
    Type: Application
    Filed: April 13, 2017
    Publication date: September 26, 2019
    Applicant: Novan, Inc.
    Inventors: Ryan DOXEY, Nathan STASKO, Megan MARTIN
  • Publication number: 20190290682
    Abstract: The invention provides compositions for producing hydrogen rich water, nutraceuticals, cosmetics, pharmaceuticals, and other products. In one embodiment, the invention provides a composition, e.g., a tablet, including magnesium metal, at least one water-soluble acid, and a binding agent. The magnesium metal and at least one water-soluble acid may be present in amounts sufficient to maintain a pH of less than 7, e.g., at a specific time period after reaction, and a concentration of at least 0.5 mM H2 after reaction in 50 mL water in a container e.g., a sealed or an open container, e.g., at least 0.5 mM H2 after reaction in 100 mL water or at least 0.5 mM H2 after reaction in 500 mL water. The composition may also include a lubricant.
    Type: Application
    Filed: July 17, 2017
    Publication date: September 26, 2019
    Inventors: Alexander TARNAVA, Richard James HOLLAND
  • Publication number: 20190290683
    Abstract: The present invention provides a pharmaceutical composition that can improve the survival time and the survival rate of a patient after onset of hemorrhagic shock. The present invention provides a gaseous pharmaceutical composition comprising hydrogen gas for improving and/or stabilizing circulatory dynamics after onset of hemorrhagic shock. The pharmaceutical composition of the present invention can be administered when blood transfusion therapy cannot be given, and can increase the survival rate after onset of hemorrhagic shock or extend the survival time compared to when the pharmaceutical composition of the present invention is not administered.
    Type: Application
    Filed: July 21, 2017
    Publication date: September 26, 2019
    Applicants: Keio University, Taiyo Nippon Sanso Corporation
    Inventors: Masaru SUZUKI, Tadashi MATSUOKA, Tomoyoshi TAMURA, Kei HAYASHIDA, Matoaki SANO
  • Publication number: 20190290684
    Abstract: The invention relates to a solid pharmaceutical tablet for oral delivery, the tablet comprising calcium carbonate in an amount of more than 30% by weight of the tablet and organic water-insoluble components in an amount of more than 20% by weight of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing the organic water-insoluble components, and wherein the tablet is adapted to release more than 80% of the calcium carbonate within 5 minutes of mastication.
    Type: Application
    Filed: March 23, 2018
    Publication date: September 26, 2019
    Inventor: JESPER NEERGAARD
  • Publication number: 20190290685
    Abstract: Large-pore mesoporous silica nanoparticles (MSN) were prepared and functionalized to serve as a robust and biocompatible delivery platform for platinum-acridine (PA) anticancer agents. The material showed a high loading capacity for the dicationic, hydrophilic hybrid agent [PtCl(en)(N-[acridin-9-ylaminoethyl]-N-methylropionamidine)] dinitrate salt (P1 Al) and virtually complete retention of payload at neutral pH in a high-chloride buffer. In acidic media mimicking the pH inside the cells' lysosomes, rapid, burst-like release of P1 A1 from the nanoparticles is observed. Coating of the materials in phospholipid bilayers resulted in nanoparticles with greatly improved colloidal stability. The lipid and carboxylate- modified nanoparticles containing 40 wt. % drug caused S phase arrest and inhibited cell proliferation in pancreatic cancer cells at submicromolar concentrations similar to carrier-free P1A1.
    Type: Application
    Filed: October 27, 2017
    Publication date: September 26, 2019
    Inventors: Ulrich Bierbach, Ye Zheng, Ravi Singh
  • Publication number: 20190290686
    Abstract: The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g. enucleated erythroid cells and platelets), that are engineered to activate or suppress T cells.
    Type: Application
    Filed: December 22, 2018
    Publication date: September 26, 2019
    Applicant: Rubius Therapeutics, Inc.
    Inventors: Thomas Joseph Wickham, Tiffany Fen-yi Chen, Sivan Elloul, Regina Sophia Salvat, Nathan J. Dowden
  • Publication number: 20190290687
    Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 26, 2019
    Inventors: Maya KORONYO, Altanchimeg RENTSENDORJ, Yosef KORONYO, Keith BLACK
  • Publication number: 20190290688
    Abstract: The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and/or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 26, 2019
    Inventors: Dafna BAR-SAGI, Jane CULLIS, Craig RAMIREZ
  • Publication number: 20190290689
    Abstract: The present invention provides a pharmaceutical preparation for use by injection into the skin, wherein the pharmaceutical preparation is preparable by a production method comprising the steps of providing a liquid collected from an organism, which liquid comprises cellular constituents of blood, providing a vessel or containment means, said vessel or containment means having an internal surface, and contacting said liquid with said vessel or containment means, wherein (a) said production method further comprises the step of incubating said liquid in said vessel or containment means for an incubation time, and optionally removing cellular constituents of said liquid after said incubation, (b) said liquid comprises exosomes, and said production method further comprises the steps of concentrating said exosomes and optionally removing cellular constituents of said liquid after said concentration, or the step of isolating said exosomes, or (c) said production method further comprises the step of avoiding incubat
    Type: Application
    Filed: May 11, 2017
    Publication date: September 26, 2019
    Applicant: ORTHOGEN AG
    Inventors: Peter WEHLING, Julio REINECKE
  • Publication number: 20190290690
    Abstract: The present invention is based on the idea of extracorporeally simulating a wound in order to obtain wound healing/regenerative growth factor mixtures. The invention provides a method for separating the growth factors that are released from cells upon coagulation (coagulation-induced signaling phase) from the growth factors that are secreted by cells under hypoxia (hypoxia-induced signaling phase), then mixing the two phases at defined ratios to obtain a novel composition. Peripheral blood is obtained and allowed to clot or centrifuged to induce clotting. The serum is removed completely or partially and replaced with fresh medium of volume equal or less than the volume of serum removed. The clot is incubated in fresh medium at a temperature of 10 to 40° C., under hypoxia (1-10% O2) for 1 to 7 days. The clot conditioned medium is then collected and mixed with the serum at a defined ratio to obtain the composition.
    Type: Application
    Filed: October 4, 2017
    Publication date: September 26, 2019
    Applicant: CULTEMA GMBH
    Inventors: Sarah Prinzessen Von Isenburg, Constance Neuhann-Lorenz
  • Publication number: 20190290691
    Abstract: The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.
    Type: Application
    Filed: June 22, 2017
    Publication date: September 26, 2019
    Inventors: Elmar Jäckel, Fatih Noyan, Michael Hust
  • Publication number: 20190290692
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof and use of cleavage enzyme.
    Type: Application
    Filed: October 11, 2017
    Publication date: September 26, 2019
    Applicant: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe, Luke Deary
  • Publication number: 20190290693
    Abstract: A PDL1 block CAR-T transgenic vector for suppressing immune escape includes: AmpR sequence containing ampicillin resistance gene (SEQ ID NO: 1); prokaryotic replicon pUC Ori sequence (SEQ ID NO: 2); virus replicon SV40 Ori sequence (SEQ ID NO: 3); eWPRE enhanced posttranscriptional regulatory element of hepatitis B virus (SEQ ID NO: 11); human EF1a promoter (SEQ ID NO: 12); lentiviral packaging cis-elements for lentiviral packaging; humanized single-chain antibody fragment PDL1scFv1 (SEQ ID NO: 21), PDL1scFv2 (SEQ ID NO: 22), or PDL1scFv3 (SEQ ID NO: 23) of human PDL1; IRES ribosome binding sequence (SEQ ID NO: 25); IL6 signal peptide (SEQ ID NO: 26); human antibody Fc segment (SEQ ID NO: 27); and chimeric antigen receptors of the second or third generation CAR for integrating recognition, transmission and initiation. A preparation method of the PDL1 block CAR-T transgenic vector and an application thereof in a preparation of anti-immune escape drugs.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 26, 2019
    Applicant: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
    Inventors: Wei QI, Lei YU, Liqing KANG, Zhou YU
  • Publication number: 20190290694
    Abstract: The present invention relates to gene editing methods to engineer primary immune cells that are made resistant to proteasome inhibitors, such as Bortezomib, Carfilzomib, Ixazomib, Marizomib, Delanzomib or Oporozomib, for their use in cell immunotherapy in combination with proteasome inhibitor treatments.
    Type: Application
    Filed: December 20, 2017
    Publication date: September 26, 2019
    Inventors: Anne-Sophie GAUTRON, Philippe DUCHATEAU, Laurent POIROT, Julien VALTON
  • Publication number: 20190290695
    Abstract: The present disclosure relates to devices for producing mature red blood cells and methods for using the same. The devices comprise micro-slit filters that mechanically stimulate cells in custom cell medium to impart the cells with physical characteristics that enable the cells to pass through and survive human vasculature.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventors: Richard Waugh, Julia M. Kuebel, Yingye Fang, Greg Palis
  • Publication number: 20190290696
    Abstract: Thw present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and/or treatment of inflammatory driven diseases, neurodegenerative diseases, immune/autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 26, 2019
    Inventor: Kyra Natalia Matahari DE MIROSCHEDJI
  • Publication number: 20190290697
    Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.
    Type: Application
    Filed: January 1, 2019
    Publication date: September 26, 2019
    Applicants: Khloris Biosciences, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
  • Publication number: 20190290698
    Abstract: The present invention provides a method of treating subjects with non-ischemic dilated cardiomyopathy by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells. The present invention also provides a method of treating subjects with symptoms of aging frailty by administering a therapeutically effective amount of an isolated population of allogeneic human mesenchymal stem cells.
    Type: Application
    Filed: November 10, 2017
    Publication date: September 26, 2019
    Applicant: Longeveron LLC
    Inventors: Joshua M. Hare, Ana Marie Landin
  • Publication number: 20190290699
    Abstract: The present invention relates to an epithelial stem/progenitor cell population isolated from the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types. The invention also relates to a pharmaceutical composition comprising such an epithelial stem/progenitor cell population or a cellular extract thereof.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 26, 2019
    Applicant: CELLRESEARCH CORPORATION PTE LTD.
    Inventors: Toan Thang PHAN, Ivor Jiun LIM
  • Publication number: 20190290700
    Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 26, 2019
    Applicant: ISLETONE AB
    Inventors: Karl HENRIK-GRINNEMO, Oscar SIMONSON, Matthias CORBASCIO, Christer SYLVÉN, Eva WÄRDELL
  • Publication number: 20190290701
    Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
    Type: Application
    Filed: February 25, 2019
    Publication date: September 26, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
  • Publication number: 20190290702
    Abstract: The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition both for ameliorating and treating perinatal brain damage including learning disability and motor disability, each of the cell preparation and the pharmaceutical composition containing SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue collected from a living body or cultured mesenchymal cells. The cell preparation according to the present invention relies on a mechanism that Muse cells are administered to a subject having the above-mentioned damage to cause the engraftment of the Muse cells in a damaged brain tissue, thereby ameliorating and treating the damage.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 26, 2019
    Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Masaaki Mizuno, Masahiro Hayakawa, Mari Dezawa
  • Publication number: 20190290703
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Application
    Filed: October 28, 2018
    Publication date: September 26, 2019
    Inventor: Elizabeth McKenna
  • Publication number: 20190290704
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Applicant: CRESTOVO HOLDINGS LLC
    Inventor: Thomas J. BORODY
  • Publication number: 20190290705
    Abstract: The present invention relates to a certain microorganism for altering the composition of oral biofilms, in particular for use in the treatment and/or prevention of dental caries and/or periodontal disease. In particular, the present invention relates to a microorganism for use as a probiotic agent for altering the bacterial composition of oral biofilms derived from saliva, preferably for reducing the proportions of Gram-negative anaerobic genera and/or increasing the proportions of aerobic or facultatively anaerobic genera. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising the microorganism as probiotic agents as well as a method of production thereof.
    Type: Application
    Filed: January 18, 2017
    Publication date: September 26, 2019
    Inventors: William WADE, Marcus Rodolf GÖTZ, Manuel PESARO
  • Publication number: 20190290706
    Abstract: The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of the symptoms of and/or for treating Irritable Bowel Syndrome (IBS) or also similar pathologies affecting the gastrointestinal apparatus. In particular, the bacteria are selected from the following genera: Lactobacillus, Bifidobacterium, Bacillus, Propionibacterium, Streptococcus, Lactococcus, Aerococcus and Enterococcus.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 26, 2019
    Applicant: SoFar S.p.A.
    Inventors: Andrea BIFFI, Walter FIORE, Ruggero ROSSI
  • Publication number: 20190290707
    Abstract: The present invention relates to a probiotic composition for preventing, improving or alleviating pancreatic cancer and a method for preventing, improving or alleviating the pancreatic cancer and its complications using the probiotic composition. The probiotic composition, which is consisted of specific strains and specific ratio of Lactobacillus paracasei to Lactobacillus reuteri, can significantly improve or alleviate various symptomatic indicators and severity of pancreatic cancer, thereby being applied on a method for preventing, improving or alleviating the pancreatic cancer and its complications using an oral composition including the Lactobacillus strains.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 26, 2019
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Wen-Ling Yeh, Ming-Shiou Jan, Yen-Wan Hsiao, Li-Jin Hsu, Junko Sugawara
  • Publication number: 20190290708
    Abstract: A bacterial composition and method that inhibits E. coli O157:H7 growth by as much as 93% and Salmonella growth by as much as 97%, together with commensurate inhibition rates against the Big-Six Escherichia coli strains referred to as the non-O157 STECs that include E. coli O121:H19; E. coli O45:H2; E. coli O103:H11; E. coli O145, E. coli O26:H11; and E. coli O111. The composition is constituted of various combinations of the following unique pathogen-inhibiting bacteria: (1) Lactobacillus animalis; (2) Enterococcus faecium (3) Pediococcus acidilactici.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Applicant: MICROBIOS, INC.
    Inventors: Matthew Ryan GARNER, Joseph F. Flint
  • Publication number: 20190290709
    Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular respiratory bacterial infections such as bacterial pneumonia. More specifically, the present invention is directed to novel bacteriophage strains, and products and cocktails thereof, including F99/10, F110/10, F27/12, Psa_F83/13, Psa_F95/13, F391/08, Kle_F92/15, Kle_F105/15, Kle_F134/15, Kle_F141/15, as well as variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including respiratory infections caused by, e.g., Pseudomonas aeruginosa and/or Klebsiella pneumoniae. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics or other standard and non-standard therapies for respiratory infections.
    Type: Application
    Filed: December 4, 2017
    Publication date: September 26, 2019
    Inventors: Sofia Valker Côrte-Real, Miguel Ângelo Costa Garcia, Clara Isabel Rodrigues Leandro, Ana Raquel Martins Barbosa
  • Publication number: 20190290710
    Abstract: The invention provides methods for the production of recombinant adeno-associated virus vectors (rAAV), comprising contacting a host cell with a solution comprising a glucocorticoid analog, such as dexamethasone. Also provided are methods for increasing the production of rAAV by a host cell, comprising contacting a host cell with a solution comprising a glucocorticoid analog, such as dexamethasone.
    Type: Application
    Filed: July 12, 2017
    Publication date: September 26, 2019
    Inventors: Ying Jing, Mingyang Jiang, Kelly Reed Clark
  • Publication number: 20190290711
    Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
    Type: Application
    Filed: March 29, 2019
    Publication date: September 26, 2019
    Inventors: Paul Fisher, Devanand Sarkar, Paul Dent
  • Publication number: 20190290712
    Abstract: A novel alga mutant having improved pigment productivity is provided. The mutant can be used to produce carotenoid-based pigments, particularly, xanthophyll by using a small amount of energy, and thus can effectively produce pigment on an industrial level. In addition, the mutant can be used as a source for foods, health functional foods, and medications which contain a pigment. Further, when account is taken of the physiological characteristics of the euryhaline microalgae Dunaliella and the geological characteristics of Korean, the three sides of which are in contact with the sea, sea-water can be used as a culture medium, with the expectation of reducing the cost and leading to the development of related industries.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 26, 2019
    Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eon Seon JIN, Min Jae KIM
  • Publication number: 20190290713
    Abstract: Disclosed here are compositions comprising powered hemp seed, an emulsified/dispersant such as lecithin (particularly soy or sunflower lecithin), Cannabis, and optionally other additives and excipients, and the methods of making these compositions. The compositions may be used for, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for appetite enhancement and the treatment of anorexia. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use, are also disclosed.
    Type: Application
    Filed: June 10, 2019
    Publication date: September 26, 2019
    Inventor: Keith Gerald Freeman
  • Publication number: 20190290714
    Abstract: A therapeutic composition for skin use composed of essential oils derived from natural plant sources and at least one carrier oil. The compositions may include fenugreek essential oil, almond essential oil, mint essential oil, garlic essential oil, and castor essential oil with coconut oil as the carrier oil. The compositions are administered topically to provide pain release.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Inventors: Farah Kashefi, Arash Naeini
  • Publication number: 20190290715
    Abstract: Açaí berry seed extracts (açai palm fruit, Euterpe oleracea) with effect in the treatment of diseases or disorders individually or jointly related to the metabolic syndrome; a process for obtaining an açai berry seed extract; a pharmaceutical and a food composition for treating diseases or disorders individually or jointly related to the metabolic syndrome, and a method for treating diseases or disorders individually or jointly associated with metabolic syndrome in humans or animals.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Inventors: André Moreira CASTILHO, Luiz Francisco PIANOWSKI, Roberto Soares de MOURA